BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38267222)

  • 1. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers.
    Qian J; Wang Q; Xiao L; Xiong W; Xian M; Su P; Yang M; Zhang C; Li Y; Zhong L; Ganguly S; Zu Y; Yi Q
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38267222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
    Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
    J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
    Qian J; Xie J; Hong S; Yang J; Zhang L; Han X; Wang M; Zhan F; Shaughnessy JD; Epstein J; Kwak LW; Yi Q
    Blood; 2007 Sep; 110(5):1587-94. PubMed ID: 17515399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TCR mimic monoclonal antibodies induce apoptosis of tumor cells via immune effector-independent mechanisms.
    Verma B; Jain R; Caseltine S; Rennels A; Bhattacharya R; Markiewski MM; Rawat A; Neethling F; Bickel U; Weidanz JA
    J Immunol; 2011 Mar; 186(5):3265-76. PubMed ID: 21282517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo.
    Chang DK; Moniz RJ; Xu Z; Sun J; Signoretti S; Zhu Q; Marasco WA
    Mol Cancer; 2015 Jun; 14():119. PubMed ID: 26062742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
    Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
    Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
    Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
    J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.
    Veomett N; Dao T; Liu H; Xiang J; Pankov D; Dubrovsky L; Whitten JA; Park SM; Korontsvit T; Zakhaleva V; Casey E; Curcio M; Kharas MG; O'Reilly RJ; Liu C; Scheinberg DA
    Clin Cancer Res; 2014 Aug; 20(15):4036-46. PubMed ID: 24850840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.
    Patterson AM; Kaabinejadian S; McMurtrey CP; Bardet W; Jackson KW; Zuna RE; Husain S; Adams GP; MacDonald G; Dillon RL; Ames H; Buchli R; Hawkins OE; Weidanz JA; Hildebrand WH
    Mol Cancer Ther; 2016 Feb; 15(2):313-22. PubMed ID: 26719579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.
    Yang J; Cao Y; Hong S; Li H; Qian J; Kwak LW; Yi Q
    Clin Cancer Res; 2009 Feb; 15(3):951-9. PubMed ID: 19188166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.
    Li R; Zheng C; Wang Q; Bi E; Yang M; Hou J; Fu W; Yi Q; Qian J
    Haematologica; 2021 Mar; 106(3):838-846. PubMed ID: 32079700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.
    Loisel S; André PA; Golay J; Buchegger F; Kadouche J; Cérutti M; Bologna L; Kosinski M; Viertl D; Delaloye AB; Berthou C; Mach JP; Boumsell L
    Mol Cancer; 2011 Apr; 10():42. PubMed ID: 21504579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
    Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
    Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
    Liu C; DeNardo G; Tobin E; DeNardo S
    Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells.
    Tomita Y; Harao M; Senju S; Imai K; Hirata S; Irie A; Inoue M; Hayashida Y; Yoshimoto K; Shiraishi K; Mori T; Nomori H; Kohrogi H; Nishimura Y
    Cancer Sci; 2011 Jan; 102(1):71-8. PubMed ID: 21087352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies.
    Ahmed M; Lopez-Albaitero A; Pankov D; Santich BH; Liu H; Yan S; Xiang J; Wang P; Hasan AN; Selvakumar A; O'Reilly RJ; Liu C; Cheung NV
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.
    Hee Lee J; Park MS; Hwang JE; Cho SH; Bae WK; Shim HJ; Kim DE; Chung IJ
    Cell Mol Immunol; 2013 May; 10(3):275-82. PubMed ID: 23524651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.